## Marie-Odile Krebs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4653321/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Relationship between jumping to conclusions and clinical outcomes in people at clinical high-risk for psychosis. Psychological Medicine, 2022, 52, 1569-1577.	4.5	11
2	A polymorphism in the glutamate metabotropic receptor 7 is associated with cognitive deficits in the early phases of psychosis. Schizophrenia Research, 2022, 249, 56-62.	2.0	10
3	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 100-110.	4.3	9
4	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biological Psychiatry, 2022, 91, 313-327.	1.3	114
5	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). Journal of Affective Disorders, 2022, 299, 367-376.	4.1	33
6	Verbal memory performance predicts remission and functional outcome in people at clinical high-risk for psychosis. Schizophrenia Research: Cognition, 2022, 28, 100222.	1.3	10
7	A novel tablet-based application for assessment of manual dexterity and its components: a reliability and validity study in healthy subjects. Journal of NeuroEngineering and Rehabilitation, 2022, 19, 35.	4.6	4
8	Dopamine-induced pruning in monocyte-derived-neuronal-like cells (MDNCs) from patients with schizophrenia. Molecular Psychiatry, 2022, 27, 2787-2802.	7.9	11
9	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	27.8	929
10	Dysmaturational Longitudinal Epigenetic Aging During Transition to Psychosis. Schizophrenia Bulletin Open, 2022, 3, .	1.7	4
11	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Molecular Psychiatry, 2021, 26, 2590-2604.	7.9	16
12	Dysregulated Lipid Metabolism Precedes Onset of Psychosis. Biological Psychiatry, 2021, 89, 288-297.	1.3	42
13	Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence. JAMA Psychiatry, 2021, 78, 77.	11.0	57
14	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. Schizophrenia Bulletin, 2021, 47, 1018-1028.	4.3	10
15	Non-cell-autonomous OTX2 transcription factor regulates anxiety-related behavior in the mouse. Molecular Psychiatry, 2021, 26, 6469-6480.	7.9	13
16	When Alterations in Social Cognition Meet Subjective Complaints in Autism Spectrum Disorder: Evaluation With the "ClaCoS―Battery. Frontiers in Psychiatry, 2021, 12, 643551.	2.6	2
17	Primary prevention of depression: An umbrella review of controlled interventions. Journal of Affective Disorders, 2021, 294, 957-970.	4.1	23
18	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	7.9	23

#	Article	IF	CITATIONS
19	Influence of polygenic risk scores for schizophrenia and resilience on the cognition of individuals at-risk for psychosis. Translational Psychiatry, 2021, 11, 518.	4.8	15
20	Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry, 2020, 77, 190.	11.0	23
21	Predicting the individual risk of psychosis conversion in at-risk mental state (ARMS): a multivariate model reveals the influence of nonpsychotic prodromal symptoms. European Child and Adolescent Psychiatry, 2020, 29, 1525-1535.	4.7	10
22	Dysregulation of peripheral expression of the YWHA genes during conversion to psychosis. Scientific Reports, 2020, 10, 9863.	3.3	12
23	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. Schizophrenia Research, 2020, 230, 104-107.	2.0	6
24	S175. CLINICAL OUTCOMES IN PEOPLE AT HIGH RISK FOR PSYCHOSIS RELATED TO INTERACTIONS BETWEEN POLYGENIC RISK SCORES AND CHILDHOOD ADVERSITY. Schizophrenia Bulletin, 2020, 46, S104-S104.	4.3	0
25	Common vs. Distinct Visuomotor Control Deficits in Autism Spectrum Disorder and Schizophrenia. Autism Research, 2020, 13, 885-896.	3.8	8
26	Prevention of Psychosis. JAMA Psychiatry, 2020, 77, 755.	11.0	287
27	Neural noise and cortical inhibition in schizophrenia. Brain Stimulation, 2020, 13, 1298-1304.	1.6	6
28	Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis. Schizophrenia Bulletin, 2020, 46, 823-833.	4.3	14
29	Reliability and correlation of mixture cell correction in methylomic and transcriptomic blood data. BMC Research Notes, 2020, 13, 74.	1.4	4
30	Stress, Cortisol and NR3C1 in At-Risk Individuals for Psychosis: A Mendelian Randomization Study. Frontiers in Psychiatry, 2020, 11, 680.	2.6	3
31	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). European Neuropsychopharmacology, 2019, 29, 1301-1311.	0.7	38
32	M51 CONVERGENT METHYLOMIC SIGNATURE OF CANNABIS EXPOSURE DURING ADOLESCENCE IN HUMAN BLOOD SAMPLES AND RAT PREFRONTAL AREA. European Neuropsychopharmacology, 2019, 29, S193.	0.7	0
33	"A circle and a triangle dancing together― Alteration of social cognition in schizophrenia compared to autism spectrum disorders. Schizophrenia Research, 2019, 210, 94-100.	2.0	34
34	Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning – Results from the EU-GEI study. European Psychiatry, 2019, 59, 52-59.	0.2	19
35	Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study. Psychiatry Research, 2019, 276, 210-217.	3.3	11
36	Impaired attentional modulation of sensorimotor control and cortical excitability in schizophrenia. Brain, 2019, 142, 2149-2164.	7.6	21

#	Article	IF	CITATIONS
37	06.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY. Schizophrenia Bulletin, 2019, 45, S177-S178.	4.3	0
38	Perinatal Exposure to Environmental Endocrine Disruptors in the Emergence of Neurodevelopmental Psychiatric Diseases: A Systematic Review. International Journal of Environmental Research and Public Health, 2019, 16, 1318.	2.6	42
39	Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders. European Journal of Pain, 2019, 23, 1225-1233.	2.8	37
40	<p>Correlation of Health-Related Quality of Life in Clinically Stable Outpatients with Schizophrenia</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 3475-3486.	2.2	8
41	Predictive Modulation of Corticospinal Excitability and Implicit Encoding of Movement Probability in Schizophrenia. Schizophrenia Bulletin, 2019, 45, 1358-1366.	4.3	8
42	Burnout in medical students before residency: A systematic review and meta-analysis. European Psychiatry, 2019, 55, 36-42.	0.2	248
43	Longitudinal Analyses of Blood Transcriptome During Conversion to Psychosis. Schizophrenia Bulletin, 2019, 45, 247-255.	4.3	24
44	Individual factors influencing the duration of untreated psychosis. Microbial Biotechnology, 2019, 13, 798-804.	1.7	9
45	Eye Movements in Psychiatry. Studies in Neuroscience, Psychology and Behavioral Economics, 2019, , 703-748.	0.3	6
46	État mental à haut risque de transition psychotique. , 2019, , 167-171.		0
47	Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study. Psychiatry Research, 2018, 267, 56-62.	3.3	26
48	Health-related quality of life in outpatients with schizophrenia: factors that determine changes over time. Social Psychiatry and Psychiatric Epidemiology, 2018, 53, 239-248.	3.1	8
49	Détection et intervention précoceÂ: un nouveau paradigme. Annales Medico-Psychologiques, 2018, 176, 65-69.	0.4	5
50	The C'JAAD: a French team for early intervention in psychosis in Paris. Microbial Biotechnology, 2018, 12, 243-249.	1.7	24
51	High-Frequency Neuronavigated rTMS in Auditory Verbal Hallucinations: A Pilot Double-Blind Controlled Study in Patients With Schizophrenia. Schizophrenia Bulletin, 2018, 44, 505-514.	4.3	37
52	Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review. Journal of Psychiatry and Neuroscience, 2018, 43, 223-244.	2.4	34
53	S118. CAN THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) DIFFERENTIATE REFRACTORY FROM NON-REFRACTORY SCHIZOPHRENIA? A FACTOR ANALYTIC INVESTIGATION BASED ON DATA FROM THE PATTERN COHORT STUDY. Schizophrenia Bulletin, 2018, 44, S371-S371.	4.3	0
54	Transdifferentiation of Human Circulating Monocytes Into Neuronal-Like Cells in 20 Days and Without Reprograming. Frontiers in Molecular Neuroscience, 2018, 11, 323.	2.9	14

#	Article	IF	CITATIONS
55	One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia. Psychiatry Research, 2018, 270, 205-210.	3.3	5
56	16.3 METHYLOMIC CHANGES OF OXIDATIVE STRESS REGULATION, AXON GUIDANCE AND INFLAMMATORY PATHWAYS DURING CONVERSION TO PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S26-S26.	4.3	0
57	Epigenetic variability in conversion to psychosis: novel findings from an innovative longitudinal methylomic analysis. Translational Psychiatry, 2018, 8, 93.	4.8	14
58	Methylomic changes during conversion to psychosis. Molecular Psychiatry, 2017, 22, 512-518.	7.9	56
59	Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study. Schizophrenia Research, 2017, 188, 89-91.	2.0	12
60	Phenotypic continuum between autism and schizophrenia: Evidence from the Movie for the Assessment of Social Cognition (MASC). Schizophrenia Research, 2017, 185, 161-166.	2.0	65
61	Oculomotricity and Neurological Soft Signs: Can we refine the endophenotype? A study in subjects belonging to the spectrum of schizophrenia. Psychiatry Research, 2017, 256, 490-497.	3.3	14
62	Conscious and unconscious performance monitoring: Evidence from patients with schizophrenia. NeuroImage, 2017, 144, 153-163.	4.2	37
63	Saccadic eye movements as markers of schizophrenia spectrum: Exploration in at-risk mental states. Schizophrenia Research, 2017, 181, 30-37.	2.0	29
64	Manual Dexterity in Schizophrenia—A Neglected Clinical Marker?. Frontiers in Psychiatry, 2017, 8, 120.	2.6	11
65	Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol. PLoS ONE, 2017, 12, e0174783.	2.5	18
66	Cognitive control deficit in patients with first-episode schizophrenia is associated with complex deviations of early brain development. Journal of Psychiatry and Neuroscience, 2017, 42, 87-94.	2.4	15
67	A Serious Game to Improve Cognitive Functions in Schizophrenia: A Pilot Study. Frontiers in Psychiatry, 2016, 7, 64.	2.6	48
68	Persistent Depersonalization/Derealization Disorder Induced by Synthetic Cannabinoids. American Journal of Psychiatry, 2016, 173, 839-840.	7.2	7
69	Exploring and visualizing multidimensional data in translational research platforms. Briefings in Bioinformatics, 2016, 18, bbw080.	6.5	25
70	Altered cortical processing of motor inhibition in schizophrenia. Cortex, 2016, 85, 1-12.	2.4	26
71	Chronic cannabinoid exposure during adolescence leads to long-term structural and functional changes in the prefrontal cortex. European Neuropsychopharmacology, 2016, 26, 55-64.	0.7	66
72	Self-reference recollection effect and its relation to theory of mind: An investigation in healthy controls and schizophrenia. Consciousness and Cognition, 2016, 42, 51-64.	1.5	6

#	Article	IF	CITATIONS
73	Altering the course of schizophrenia: progress and perspectives. Nature Reviews Drug Discovery, 2016, 15, 485-515.	46.4	410
74	Paradoxical Improvement of Schizophrenic Symptoms by a Dopaminergic Agonist: An Example of Personalized Psychiatry in a Copy Number Variation–Carrying Patient. Biological Psychiatry, 2016, 80, e21-e23.	1.3	7
75	Salivary cortisol in early psychosis: New findings and meta-analysis. Psychoneuroendocrinology, 2016, 63, 262-270.	2.7	76
76	Confidence and psychosis: a neuro-computational account of contingency learning disruption by NMDA blockade. Molecular Psychiatry, 2016, 21, 946-955.	7.9	77
77	Mutation Burden of Rare Variants in Schizophrenia Candidate Genes. PLoS ONE, 2015, 10, e0128988.	2.5	17
78	"Who is talking to me?―— Self–other attribution of auditory hallucinations and sulcation of the right temporoparietal junction. Schizophrenia Research, 2015, 169, 95-100.	2.0	28
79	Cognitive remediation therapy (CRT) benefits more to patients with schizophrenia with low initial memory performances. Disability and Rehabilitation, 2015, 37, 846-853.	1.8	18
80	Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Translational Psychiatry, 2015, 5, e601-e601.	4.8	134
81	Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern study. Schizophrenia Research, 2015, 169, 234-240.	2.0	29
82	Thérèse LempérièreÂ: ses travaux sur les psychotropes et perspectives actuelles. Annales Medico-Psychologiques, 2015, 173, 799-803.	0.4	0
83	Deviations in cortex sulcation associated with visual hallucinations in schizophrenia. Molecular Psychiatry, 2015, 20, 1101-1107.	7.9	42
84	Chapitre 5. «ÂModes d'entrée»Â: desÂprodromes auÂpremier épisode psychotique. , 2015, , 67-86.		0
85	Chapitre 8. Marqueurs moléculaires etÂbiologiques. , 2015, , 125-142.		0
86	Chapitre 7. Troubles cognitifs précoces dansÂlaÂpsychose débutante. , 2015, , 109-124.		0
87	Chapitre 4. Modèles physiopathologiquesÂ: modèle neurodéveloppemental, maturation cérébrale et«ÂdoubleÂhit». , 2015, , 53-66.		0
88	Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. Frontiers in Neuroscience, 2014, 8, 361.	2.8	108
89	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.3	229
90	Reading impairment in schizophrenia: Dysconnectivity within the visual system. Neuropsychologia, 2014, 53, 187-196.	1.6	15

#	Article	IF	CITATIONS
91	Family-based association study of common variants, rare mutation study and epistatic interaction detection in HDAC genes in schizophrenia. Schizophrenia Research, 2014, 160, 97-103.	2.0	23
92	Subjects at Ultra High Risk for psychosis have â€~heterogeneous' intellectual functioning profile: A multiple-case study. Schizophrenia Research, 2014, 152, 415-420.	2.0	16
93	Limbic versus cognitive target for deep brain stimulation in treatment-resistant depression: Accumbens more promising than caudate. European Neuropsychopharmacology, 2014, 24, 1229-1239.	0.7	56
94	Episodic memory and self-reference via semantic autobiographical memory: insights from an fMRI study in younger and older adults. Frontiers in Behavioral Neuroscience, 2014, 8, 449.	2.0	34
95	Deficient Grip Force Control in Schizophrenia: Behavioral and Modeling Evidence for Altered Motor Inhibition and Motor Noise. PLoS ONE, 2014, 9, e111853.	2.5	14
96	Chapitre 12. Addiction au cannabis et troubles psychiatriques. , 2014, , 207-221.		0
97	Neurological soft signs in nonâ€psychotic patients with cannabis dependence. Addiction Biology, 2013, 18, 214-221.	2.6	20
98	Hyperfrontality and hypoconnectivity during refreshing in schizophrenia. Psychiatry Research - Neuroimaging, 2013, 211, 226-233.	1.8	14
99	Investigation of rare variants in LRP1, KPNA1, ALS2CL and ZNF480 genes in schizophrenia patients reflects genetic heterogeneity of the disease. Behavioral and Brain Functions, 2013, 9, 9.	3.3	15
100	Long-term cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison. Psychopharmacology, 2013, 225, 781-790.	3.1	74
101	Neuronal activity correlated with checking behaviour in the subthalamic nucleus of patients with obsessive–compulsive disorder. Brain, 2013, 136, 304-317.	7.6	33
102	Cortex Morphology in First-Episode Psychosis Patients With Neurological Soft Signs. Schizophrenia Bulletin, 2013, 39, 820-829.	4.3	70
103	Age-Related Changes in the Functional Network Underlying Specific and General Autobiographical Memory Retrieval: A Pivotal Role for the Anterior Cingulate Cortex. PLoS ONE, 2013, 8, e82385.	2.5	46
104	Don't be Too Strict with Yourself! Rigid Negative Self-Representation in Healthy Subjects Mimics the Neurocognitive Profile of Depression for Autobiographical Memory. Frontiers in Behavioral Neuroscience, 2013, 7, 41.	2.0	25
105	Diethylstilbestrol and risk of psychiatric disorders: A critical review and new insights. World Journal of Biological Psychiatry, 2012, 13, 84-95.	2.6	21
106	A step toward an objective quantification of subtle neurological signs in schizophrenia. Psychiatry Research, 2012, 198, 230-234.	3.3	7
107	Impaired saccadic adaptation in schizophrenic patients with high neurological soft sign scores. Psychiatry Research, 2012, 199, 12-18.	3.3	15
108	Poster #260 IMAGING-GENETIC STUDY OF COMT EFFECT ON CORTICAL MORPHOLOGY IN A LARGE SAMPLE OF HEALTHY SUBJECTS. Schizophrenia Research, 2012, 136, S279-S280.	2.0	0

#	Article	IF	CITATIONS
109	De Novo SYNGAP1 Mutations in Nonsyndromic Intellectual Disability and Autism. Biological Psychiatry, 2011, 69, 898-901.	1.3	164
110	Increased exonic de novo mutation rate in individuals with schizophrenia. Nature Genetics, 2011, 43, 860-863.	21.4	392
111	Factoring neurotrophins into a neurite-based pathophysiological model of schizophrenia. Progress in Neurobiology, 2011, 94, 77-90.	5.7	26
112	Neurological Soft Signs in OCD Patients With Early Age at Onset, Versus Patients With Schizophrenia and Healthy Subjects. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 409-416.	1.8	21
113	Ultra-Resistant Schizophrenia Is Not Associated With the Multidrug-Resistant Transporter 1 (MDR1) Gene rs1045642 Variant. Journal of Clinical Psychopharmacology, 2011, 31, 236-238.	1.4	5
114	Is cannabis responsible for early onset psychotic illnesses?. Neuropsychiatry, 2011, 1, 203-207.	0.4	4
115	CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis. Addiction Biology, 2011, 16, 1-6.	2.6	65
116	Correlations of cerebello-thalamo-prefrontal structure and neurological soft signs in patients with first-episode psychosis. Acta Psychiatrica Scandinavica, 2011, 123, 451-458.	4.5	59
117	The role of BDNF genetic polymorphisms in bipolar disorder with psychiatric comorbidities. Journal of Affective Disorders, 2011, 131, 307-311.	4.1	27
118	Confirmation of the factorial structure of temperamental autoquestionnaire TEMPS-A in non-clinical young adults and relation to current state of anxiety, depression and to schizotypal traits. Journal of Affective Disorders, 2011, 131, 37-44.	4.1	27
119	The 5-HTTLPR polymorphism, impulsivity and suicide behavior in euthymic bipolar patients. Journal of Affective Disorders, 2011, 133, 221-226.	4.1	43
120	Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Human Genetics, 2011, 130, 563-573.	3.8	237
121	Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol. Journal of Psychopharmacology, 2011, 25, 822-835.	4.0	21
122	Association of Inflammation Genes with Alcohol Dependence/Abuse: A Systematic Review and a Meta-Analysis. European Addiction Research, 2011, 17, 146-153.	2.4	17
123	Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Translational Psychiatry, 2011, 1, e55-e55.	4.8	205
124	Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia. Pharmacogenomics Journal, 2011, 11, 267-273.	2.0	39
125	Inflexible information acquisition strategies mediate visuo-spatial reasoning in stabilized schizophrenia patients. World Journal of Biological Psychiatry, 2011, 12, 608-619.	2.6	10
126	Variable individual sensitivity to cannabis in patients with schizophrenia. International Journal of Neuropsychopharmacology, 2010, 13, 1145-1154.	2.1	24

#	Article	IF	CITATIONS
127	Epigenetics and depression: current challenges and new therapeutic options. Current Opinion in Psychiatry, 2010, 23, 588-592.	6.3	72
128	Episodic memory and impairment of an early encoding process in schizophrenia Neuropsychology, 2010, 24, 101-108.	1.3	19
129	Direct Measure of the De Novo Mutation Rate in Autism and Schizophrenia Cohorts. American Journal of Human Genetics, 2010, 87, 316-324.	6.2	222
130	De Novo Mutations in FOXP1 in Cases with Intellectual Disability, Autism, and Language Impairment. American Journal of Human Genetics, 2010, 87, 671-678.	6.2	200
131	Real world referencing and schizophrenia: Are we experiencing the same reality?. Neuropsychologia, 2010, 48, 2922-2930.	1.6	35
132	Impulsivity and sensation seeking in alcohol abusing patients with schizophrenia. Frontiers in Psychiatry, 2010, 1, 135.	2.6	61
133	De novo mutations in the gene encoding the synaptic scaffolding protein <i>SHANK3</i> in patients ascertained for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7863-7868.	7.1	361
134	Attention and visual orienting in siblings, schizophrenic patients, and controls: Impairment in attentional disengagement. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 449-454.	1.3	7
135	De Novo Truncating Mutation in Kinesin 17 Associated with Schizophrenia. Biological Psychiatry, 2010, 68, 649-656.	1.3	43
136	Decrease of Prefrontal Metabolism After Subthalamic Stimulation in Obsessive-Compulsive Disorder: A Positron Emission Tomography Study. Biological Psychiatry, 2010, 68, 1016-1022.	1.3	111
137	AUTISTIC TRAITS AND DEVELOPMENTAL MARKERS IN ADULT ONSET SCHIZOPHRENIA. Schizophrenia Research, 2010, 117, 139.	2.0	0
138	Altered semantic but not phonological verbal fluency in young help-seeking individuals with ultra high risk of psychosis. Schizophrenia Research, 2010, 123, 53-58.	2.0	46
139	Impulsivity and sensation seeking in cannabis abusing patients with schizophrenia. Schizophrenia Research, 2010, 123, 278-280.	2.0	22
140	Neuropathological and Reelin Deficiencies in the Hippocampal Formation of Rats Exposed to MAM; Differences and Similarities with Schizophrenia. PLoS ONE, 2010, 5, e10291.	2.5	30
141	Neurological soft signs and schizotypal dimensions in unaffected siblings of patients with schizophrenia. Psychiatry Research, 2010, 175, 22-26.	3.3	38
142	Neurological soft signs in patients with schizophrenia and their unaffected siblings: frequency and correlates in two ethnic and socioeconomic distinct populations. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 218-226.	3.2	36
143	Behavioral Perturbations After Prenatal Neurogenesis Disturbance in Female Rat. Neurotoxicity Research, 2009, 15, 311-320.	2.7	47
144	IMAGING STUDY: Exposure to smoking cues during an emotion recognition task can modulate limbic fMRI activation in cigarette smokers. Addiction Biology, 2009, 14, 469-477.	2.6	24

#	Article	IF	CITATIONS
145	Potential application as screening and drug designing tools of cytoarchitectural deficiencies present in three animal models of schizophrenia. Expert Opinion on Drug Discovery, 2009, 4, 257-278.	5.0	6
146	Correlates between neurological soft signs and saccadic parameters in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 676-681.	4.8	13
147	One-carbon metabolism and schizophrenia: current challenges and future directions. Trends in Molecular Medicine, 2009, 15, 562-570.	6.7	76
148	Mutations in <i>SYNGAP1</i> in Autosomal Nonsyndromic Mental Retardation. New England Journal of Medicine, 2009, 360, 599-605.	27.0	282
149	Interaction of dopamine D1 with NMDA NR1 receptors in rat prefrontal cortex. European Neuropsychopharmacology, 2009, 19, 296-304.	0.7	50
150	Clozapine-Induced Serositis. Clinical Neuropharmacology, 2009, 32, 219-223.	0.7	23
151	Comparing effects of perceptual and reflective repetition on subjective experience during later recognition memory. Consciousness and Cognition, 2008, 17, 753-764.	1.5	13
152	New evidences of gene and environment interactions affecting prenatal neurodevelopment in schizophrenia-spectrum disorders: A family dermatoglyphic study. Schizophrenia Research, 2008, 103, 209-217.	2.0	31
153	Subthalamic Nucleus Stimulation in Severe Obsessive–Compulsive Disorder. New England Journal of Medicine, 2008, 359, 2121-2134.	27.0	829
154	Amyloid precursor protein cytoplasmic domain antagonizes reelin neurite outgrowth inhibition of hippocampal neurons. Neurobiology of Aging, 2008, 29, 542-553.	3.1	42
155	Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1: A new genetic model for Parkinson's disease?. Parkinsonism and Related Disorders, 2008, 14, S107-S111.	2.2	18
156	Memory-guided saccade abnormalities in schizophrenic patients and their healthy, full biological siblings. Psychological Medicine, 2008, 38, 861-870.	4.5	34
157	Polymorphisms of coding trinucleotide repeats of homeogenes in neurodevelopmental psychiatric disorders. Psychiatric Genetics, 2008, 18, 295-301.	1.1	19
158	Predictive saccades are impaired in biological nonpsychotic siblings of schizophrenia patients. Journal of Psychiatry and Neuroscience, 2008, 33, 17-22.	2.4	7
159	Progressive Loss of Dopaminergic Neurons in the Ventral Midbrain of Adult Mice Heterozygote for Engrailed1. Journal of Neuroscience, 2007, 27, 1063-1071.	3.6	148
160	The Role of the Cerebellum in Schizophrenia: an Update of Clinical, Cognitive, and Functional Evidences. Schizophrenia Bulletin, 2007, 34, 155-172.	4.3	256
161	Sensory dysfunction is correlated to cerebellar volume reduction in early schizophrenia. Schizophrenia Research, 2007, 91, 266-269.	2.0	30
162	Polymorphisms TaqI A of the DRD2, Ball of the DRD3, exon III repeat of the DRD4, and 3′ UTR VNTR of the DAT: Association with childhood ADHD in male African aribbean cocaine dependents?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 1034-1041.	1.7	39

#	Article	IF	CITATIONS
163	Alterations in prefrontal glutamatergic and noradrenergic systems following MK-801 administration in rats prenatally exposed to methylazoxymethanol at gestational dayÂ17. Psychopharmacology, 2007, 192, 373-383.	3.1	18
164	Validity of the CAGE questionnaire in schizophrenic patients with alcohol abuse and dependence. Schizophrenia Research, 2006, 81, 151-155.	2.0	23
165	Peri-pubertal maturation after developmental disturbance: A model for psychosis onset in the rat. Neuroscience, 2006, 143, 395-405.	2.3	130
166	Association study of the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia. BMC Genetics, 2006, 7, 34.	2.7	9
167	(AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics Journal, 2006, 6, 126-130.	2.0	81
168	Data mining based Bayesian networks for best classification. Computational Statistics and Data Analysis, 2006, 51, 1278-1292.	1.2	21
169	The French version of the validated short TEMPS-A: The temperament evaluation of Memphis, Pisa, Paris and San Diego. Journal of Affective Disorders, 2006, 96, 271-273.	4.1	22
170	Postnatal effect of embryonic neurogenesis disturbance on reelin level in organotypic cultures of rat hippocampus. Brain Research, 2006, 1097, 43-51.	2.2	12
171	Specific pattern of attentional changes in impulsive individuals. Cognitive Neuropsychiatry, 2006, 11, 452-464.	1.3	2
172	Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants. NeuroReport, 2005, 16, 1407-1410.	1.2	53
173	Support for the association between the rare functional variant I425V of the serotonin transporter gene and susceptibility to obsessive compulsive disorder. Molecular Psychiatry, 2005, 10, 1059-1061.	7.9	46
174	Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia. Journal of Psychiatric Research, 2005, 39, 391-398.	3.1	44
175	Population-based and family-based association study of 5′UTR polymorphism of the reelin gene and schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 137B, 51-55.	1.7	40
176	Cannabis Use and Schizophrenia. American Journal of Psychiatry, 2005, 162, 401-a-402.	7.2	12
177	The Use of Bayesian Networks for Subgrouping Heterogeneous Diseases. Lecture Notes in Computer Science, 2005, , 1140-1148.	1.3	0
178	Future contributions on genetics. World Journal of Biological Psychiatry, 2005, 6, 49-55.	2.6	3
179	Admixture analysis of age at onset in obsessive–compulsive disorder. Psychological Medicine, 2005, 35, 237-243.	4.5	113
180	Schizophrénies : actualités étiopathogéniques et cliniques. Bulletin De L'Academie Nationale De Medecine, 2005, 189, 935-947.	0.0	0

#	Article	IF	CITATIONS
181	Neurological and morphological anomalies and the genetic liability to schizophrenia: a composite phenotype. Schizophrenia Research, 2004, 67, 23-31.	2.0	78
182	Minor physical anomalies in patients with schizophrenia and their parents: prevalence and pattern of craniofacial abnormalities. Psychiatry Research, 2004, 125, 21-28.	3.3	74
183	Cerebellum development and schizophrenia: an association study of the human homeogene Engrailed 2. Psychiatry Research, 2004, 126, 93-98.	3.3	5
184	Nicotine use in schizophrenia and disinhibition. Psychiatry Research, 2004, 128, 229-234.	3.3	26
185	Working memory deficits in adult rats after prenatal disruption of neurogenesis. Behavioural Pharmacology, 2004, 15, 287-292.	1.7	117
186	Effects of atypical neuroleptics on alertness and visual orienting in stabilized schizophrenic patients: a preliminary study. International Journal of Neuropsychopharmacology, 2004, 7, 255-263.	2.1	16
187	Maternal transmission disequilibrium of the glutamate receptor GRIK2 in schizophrenia. NeuroReport, 2004, 15, 1987-1991.	1.2	56
188	Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder. NeuroReport, 2004, 15, 699-702.	1.2	82
189	Association between the dopamine receptor D4 (DRD4) gene and obsessiveâ€compulsive disorder. American Journal of Medical Genetics Part A, 2003, 116B, 55-59.	2.4	74
190	Apolipoprotein E in schizophrenia: A French association study and metaâ€analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2003, 119B, 18-23.	1.7	23
191	Neurological soft-signs and minor physical anomalies in schizophrenia: differential transmission within families. Schizophrenia Research, 2003, 63, 181-187.	2.0	57
192	Correlation between clinical syndromes and neuropsychological tasks in unmedicated patients with recent onset schizophrenia. Psychiatry Research, 2002, 113, 83-92.	3.3	47
193	Absence of association between a polymorphic GGC repeat in the 5′ untranslated region of the reelin gene and autism. Molecular Psychiatry, 2002, 7, 801-804.	7.9	96
194	Clinical features of panic attacks in schizophrenia. European Psychiatry, 2001, 16, 349-353.	0.2	34
195	Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Research, 2001, 102, 65-72.	3.3	135
196	Impairment of predictive saccades in schizophrenia. NeuroReport, 2001, 12, 465-469.	1.2	28
197	Is Substance Abuse in Schizophrenia Related to Impulsivity, Sensation Seeking, or Anhedonia?. American Journal of Psychiatry, 2001, 158, 492-494.	7.2	124
198	Histamine H2 receptor gene variants: lack of association with schizophrenia. Molecular Psychiatry, 2000, 5, 159-164.	7.9	33

#	Article	IF	CITATIONS
199	Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Molecular Psychiatry, 2000, 5, 558-562.	7.9	170
200	Validation and factorial structure of a standardized neurological examination assessing neurological soft signs in schizophrenia. Schizophrenia Research, 2000, 45, 245-260.	2.0	133
201	Genetic vulnerability to drug abuse. European Psychiatry, 2000, 15, 109-114.	0.2	28
202	Dopamine D3 receptor gene variants and substance abuse in schizophrenia. Molecular Psychiatry, 1998, 3, 337-341.	7.9	75
203	Clinical spectrum of CADASIL: a study of 7 families. Lancet, The, 1995, 346, 934-939.	13.7	670
204	Does bicuculline antagonize NMDA receptors? Further evidence in the rat striatum. Brain Research, 1994, 634, 345-348.	2.2	8
205	Presynaptic Regulation of Dopamine Release in Striatal Compartments and Functional Heterogeneity of the Matrix. Advances in Behavioral Biology, 1994, , 411-419.	0.2	1
206	Local GABAergic regulation of the N-methyl-d-aspartate-evoked release of dopamine is more prominent in striosomes than in matrix of the rat striatum. Neuroscience, 1993, 57, 249-260.	2.3	42
207	Glutamatergic Control of Dopamine Release in the Rat Striatum: Evidence for Presynaptic N-Methyl-D-Aspartate Receptors on Dopaminergic Nerve Terminals. Journal of Neurochemistry, 1991, 56, 81-85.	3.9	341
208	Involvement of NMDA Receptors in the Presynaptic Regulation of Dopamine Release in Striosome-and Matrix-enriched Areas of the Rat Striatum. , 1991, , 107-108.		0
209	Glycine potentiates the NMDA-induced release of dopamine through a strychnine-insensitive site in the rat striatum. European Journal of Pharmacology, 1989, 166, 567-570.	3.5	61
210	Caregiving-related experiences associated with depression severity and its symptomatology among caregivers of individuals with a severe mental disorder: an online cross-sectional study. European Archives of Psychiatry and Clinical Neuroscience, 0, , .	3.2	0